With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

New From MSK Report:

Learn what your patients are reading in the popular press:

Consumer News: Pain Relief for Some, With an Odd Tradeoff
A new device implanted near the spine offers relief for some chronic pain sufferers...

Keep up-to-date with what is on PubMed:

New from PubMed: Tacrolimus in Dermatology- Pharmacokinetics, Mechanism of Action, Drug Interactions, Dosages, and Side Effects
Researchers have assessed the efficacy and safety of tacrolimus treatment in dermatology...

MSK Report News:

Bones: FDA Warns of Severe Bone, Joint, Muscle Pain Linked to Bisphosphonates
FDA warning highlights "severe and sometimes incapacitating" musculoskeletal pain in patients taking bisphosphonates...

BioPharm Business: Salix Submits Granulated Mesalamine NDA to US FDA as Once Daily Dosing for Maintenance of UC Remission; Colazal (balsalazide disodium) for UC Goes Generic
Salix Pharmaceuticals, Ltd, a developer and marketer of prescription pharmaceutical products for the treatment of gastrointestinal diseases, announced that it is seeking approval to market granulated mesalamine as a once daily treatment for the maintenance of ulcerative colitis (UC) remission in patients...

BioPharm Business: Abbott's Humira Approved in the EU for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott announced it has received marketing authorization from the European Commission for the use of the TNF antagonist Humira (adalimumab) as a treatment for moderate-to-severe plaque psoriasis. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis...

BioPharm Business: Neurochem's Eprodisate (Kiacta) for the treatment of AA Amyloidosis Receives Negative Opinion from CHMP; Decision by US FDA Expected April 2008
Neurochem (International) Ltd, a wholly-owned subsidiary of Neurochem Inc, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a negative opinion recommending refusal of the marketing authorization application for eprodisate (Kiacta) for the treatment of Amyloid A (AA) amyloidosis...

To remove your e-mail address from our mailing list, please reply to this e-mail with "unsubscribe" in the subject line. For questions and comments regarding this newsletter please contact .